US Capitol Capsule: Embracing The 'Megafund' Strategy: Rescuing Biopharma Investment
This article was originally published in Scrip
Executive Summary
Even in light of the economic rebound in the U.S. in recent years, public and private investment in the biopharmaceutical industry has remained tempered – mostly due to investors' concerns about the time it takes to see a return on investment and the risky nature of drug development – although venture capital invested in biotechs in the past couple of years has significantly improved, particularly in 2015.